Is UroGen Pharma (URGN) Finally Worth Your Time? What Does Stifel Nicolaus Think?

September 15, 2018 - By Ann Prendergast

Why Has Stifel Nicolaus Given UroGen Pharma (URGN) a $70 Price Target

Research professionals at Stifel Nicolaus gave a key “Buy” rating for UroGen Pharma (URGN). The firm initiated coverage in analysts note revealed to investors and clients on 14 September. The PT would indicate upside of 51.65 % from the current stock price.

UroGen Pharma Ltd. (NASDAQ:URGN) Ratings Coverage

Among 4 analysts covering Urogen Pharma Ltd (URGN), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Urogen Pharma Ltd has $7500 highest and $62.0 lowest target. $68’s average target is 47.31% above currents $46.16 stock price. Urogen Pharma Ltd had 7 analyst reports since March 15, 2018 according to SRatingsIntel. The firm has “Buy” rating by Oppenheimer given on Tuesday, May 15. The rating was maintained by Oppenheimer with “Buy” on Thursday, March 15. The rating was maintained by Oppenheimer on Tuesday, May 22 with “Buy”. Jefferies maintained the shares of URGN in report on Friday, March 16 with “Buy” rating. Ladenburg maintained the shares of URGN in report on Friday, March 16 with “Buy” rating. Oppenheimer maintained UroGen Pharma Ltd. (NASDAQ:URGN) on Tuesday, April 3 with “Buy” rating. As per Wednesday, April 4, the company rating was upgraded by Raymond James.

The stock increased 3.57% or $1.59 during the last trading session, reaching $46.16. About 36,201 shares traded. UroGen Pharma Ltd. (URGN) has risen 53.87% since September 15, 2017 and is uptrending. It has outperformed by 38.25% the S&P500.

Analysts await UroGen Pharma Ltd. (NASDAQ:URGN) to report earnings on November, 13. They expect $-1.09 earnings per share, down 5,350.00 % or $1.07 from last year’s $-0.02 per share. After $-1.14 actual earnings per share reported by UroGen Pharma Ltd. for the previous quarter, Wall Street now forecasts -4.39 % EPS growth.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company has market cap of $731.79 million. The Company’s lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water formulation as an adjuvant, or supplemental post-surgery, therapy. It currently has negative earnings. The firm is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.

Another recent and important UroGen Pharma Ltd. (NASDAQ:URGN) news was published by Seekingalpha.com which published an article titled: “Premarket analyst action – healthcare” on September 14, 2018.

UroGen Pharma Ltd. (NASDAQ:URGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.